Piperidine → Methyl 1-oxo-2-(2-piperidin-1-ylethyl)-1,2-dihydroisoquinoline-7-carboxylate

HRID 1616156노트

반응식

HRID 1616156 반응식
Br[CH2:2][CH2:3][N:4]1[CH:13]=[CH:12][C:11]2[C:6](=[CH:7][C:8]([C:14]([O:16][CH3:17])=[O:15])=[CH:9][CH:10]=2)[C:5]1=[O:18].[NH:19]1[CH2:24][CH2:23][CH2:22][CH2:21][CH2:20]1>>[O:18]=[C:5]1[C:6]2[C:11](=[CH:10][CH:9]=[C:8]([C:14]([O:16][CH3:17])=[O:15])[CH:7]=2)[CH:12]=[CH:13][N:4]1[CH2:3][CH2:2][N:19]1[CH2:24][CH2:23][CH2:22][CH2:21][CH2:20]1

참가 물질

3

실험 절차

The title compound was prepared from methyl 2-(2-bromoethyl)-1-oxo-1,2-dihydroisoquinoline-7-carboxylate (96 mg, 0.31 mmol) and piperidine (0.31 mL, 3.1 mmol) following the procedure outlined in Example 44, step 2 (80 mg, 82%). LC-MS: (FA) ES+ 315.

출처 및 근거

ORD 기록
ord-56d14f495fff4f3d82baa13fd9c4dc37
출처 데이터셋
uspto-grants-2014_07
특허 번호
US08765773B2

반응 노트

불러오는 중…